+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031

25 March 2021

Visiongain has published a new report on Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031: Forecasts by Product (Lucentis, Eylea, Avastin, Visudyne, Others), by Indication (AMD, Diabetic, Macular, Edema, Diabetic, Retinopathy, Retinal Vein, Occlusion, Others), by End-User (Hospital Pharmacy, Retail, Pharmacy, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

Global macular degeneration (AMD) and other retinal diseases drugs market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. Rising investment in drug R&D by pharmaceutical and biopharmaceutical companies, increasing prevalence of retinal diseases, mounting demand for biologics & biosimilars, and developing healthcare infrastructure in emerging economies are some of the major factors that drive the market growth.

COVID-19 Impact on Cell based assay Market
Since the COVID-19 virus outbreak in December 2019, the World Health Organization declared it a public health emergency. The disease has spread to over 100 countries and caused huge losses of lives around the globe. The descending burden on the world economy that once showed signs of recovery in the previous period has increased again. The outbreak of the epidemic has added risk factors to the already weak growth of the world economy. Many international organizations have pointed out that the world economy is in the most severe period since the financial crisis. The negative global impacts of the coronavirus are already there, significantly affecting the Macular Degeneration (AMD) and Other Retinal Diseases market in 2020. However, it is anticipated to create lucrative opportunities in near future in the macular degeneration (AMD) and other retinal diseases market.

People with a history of coagulation plus macular degeneration disorders were at increased risk of dying from COVID 19 infection. Thus, ophthalmologic specialists, necessarily focused their efforts on the ophthalmologic care of patients and are concerned about resultant potential vision loss from missing treatment. Several ways are considered to improve delivery of retinal care such as, providing home injections with appropriate protection, accelerate the development of long-acting anti–VEGF therapeutics which would reduce the frequency of clinic visits. Thus, this will help give boost to the Global Macular Degeneration (AMD) and Other Retinal Diseases market post 2020. This report studies and analyses the in-depth impact of Coronavirus COVID-19 on the Macular Degeneration (AMD) and Other Retinal Diseases industry.

Market Drivers
There is an alarming rise in the incidence of eye-related diseases, especially in developed countries, which in turn is anticipated to drive the growth of the global retinal drugs market during the forecast period. The rising number of geriatric populations all over the world is creating the high-level demand in wet macular degeneration market. According to the World Health Organization (WHO) report, the percentage of old people (above 60 years) is expected to become 21.1% by the year 2050. The total number of old age people all over the world is probable to reach 2 billion in 2050. All these statistics represent the high demand for the products for the treatment of wet macular degeneration globally in coming future. The technological advancements in the diagnosis of macular degeneration and appropriate reimbursement circumstances are driving the growth of the market.

Market Opportunities
Several initiatives have been undertaken across the globe to spread awareness about diagnosis and treatment methods of ophthalmic diseases. The International Centre for Eye Health focuses on increasing awareness about eye health problems and treatment, the World Glaucoma Association has been arranging World Glaucoma Congress for the past six years to increase awareness and discussion about glaucoma treatment advancements. Macular Degeneration Association, Inc. arranges seminars every month across various places to increase treatment penetration for age-related macular degeneration (AMD). These initiatives are expected to increase the adoption of various treatment methods which in turn is projected to fuel the growth of the market.

Competitive Landscape
Macular Degeneration (AMD) and Other Retinal Diseases market is a highly competitive market with several global and local players. Some of the leading players in this market include, Novartis AG, F. Hoffmann-La Roche, Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Bayer AG, Pfizer Inc., Regeneron Pharmaceuticals, Bausch & Lomb Incorporated, Apellis Pharmaceuticals, Santen Pharmaceuticals, Alimera Sciences, AbbVie Inc., IVERIC bio, Inc. (Formerly Ophthotech), Graybug Vision, Inc., Kubota Vision Inc.

The current competitive landscape of the Global Macular Degeneration (AMD) and Other Retinal Diseases market is highly consolidated with limited number of players operating in the market. Eylea from Regeneron Pharmaceuticals, Inc is an approved prominent therapy for major retinal diseases such as, AMD, DME, RVO. The product has strengthened its position in the market. Other products dominate the market are anti-VEGF agents such as, Lucentis by Roche. Other major strategies acquired by the leading players are collaborations, M&A, high investment in R&D, new product launches, and geographical expansion. These strategies help the companies to reinforce their existing product portfolio and regional reach. For instance, in September 2020, Bausch Health and Allegro Ophthalmics, LLC, a biopharmaceutical company announced that Bausch Health has entered into a strategic agreement to acquire all ophthalmology assets of Allegro

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Cancer Immunotherapy Market

The global Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034

11 June 2024


Biological Safety Testing Market

The global Biological Safety Testing market is projected to grow at a CAGR of 12.6% by 2034

11 June 2024


CAR-T Therapy Market

The global CAR-T Therapy market is projected to grow at a CAGR of 35.9% by 2034

11 June 2024


Synthetic Immunology Market

The global Synthetic Immunology market is projected to grow at a CAGR of 25.6% by 2034

05 June 2024